Advancements in Targeted Therapies for Colorectal Cancer: Overcoming Challenges and Exploring Future Directions.

Cancers (Basel) · 2025 · PMC12427229 · PMID 40940907

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

did not reach statistical significancep = 0.07so close (0.05 < p ≤ 0.1)

In this study, there was a trend towards an improvement in survival in the panitumumab group, but this did not reach statistical significance—23.9 months vs. 19.7 months ( p = 0.07).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.